Moloney Securities Asset Management, LLC Unity Biotechnology, Inc. Transaction History

Moloney Securities Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$0.72 - $1.86 $7,920 - $20,460	-11,000 Closed	0 $0
Q4 2021 Jan 28, 2022	SELL	$1.3 - $3.17 $13,000 - $31,700	-10,000 Reduced 47.62%	11,000 $16,000
Q3 2021 Oct 27, 2021	BUY	$2.91 - $4.5 $61,110 - $94,500	21,000 New	21,000 $63,000
Q1 2021 Apr 28, 2021	SELL	$5.51 - $9.42 $231,144 - $395,169	-41,950 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$3.42 - $6.36 $11,970 - $22,260	-3,500 Reduced 7.7%	41,950 $220,000
Q3 2020 Oct 20, 2020	BUY	$2.94 - $12.43 $70,560 - $298,320	24,000 Added 111.89%	45,450 $157,000
Q2 2020 Jul 31, 2020	SELL	$5.28 - $9.67 $161,040 - $294,935	-30,500 Reduced 58.71%	21,450 $186,000
Q1 2020 May 08, 2020	SELL	$5.0 - $7.6 $157,500 - $239,400	-31,500 Reduced 37.75%	51,950 $301,000
Q4 2019 Feb 06, 2020	BUY	$5.99 - $8.38 $439,965 - $615,511	73,450 Added 734.5%	83,450 $602,000
Q3 2019 Nov 01, 2019	SELL	$5.62 - $9.63 $39,340 - $67,410	-7,000 Reduced 41.18%	10,000 $61,000
Q2 2019 Jul 29, 2019	BUY	$7.59 - $10.21 $129,030 - $173,570	17,000 New	17,000 $162,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Moloney Securities Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Moloney Securities Asset Management, LLC with notifications on news.